N-氰基-4-吗啉甲脒 | 18413-22-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-氰基-4-吗啉甲脒
• 英文名称: N1-(morpholine)cyanoguanidine
• 英文别名: N'-cyanomorpholine-4-carboximidamide
• CAS: 18413-22-4
• 化学式: C₆H₁₀N₄O
• 分子量: 154.172
• InChiKey: RCOJSOGIWPNJPW-UHFFFAOYSA-N

物化性质

• 沸点：
  237.0±50.0 °C(Predicted)
• 密度：
  1.32±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  74.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  N-氰基-4-吗啉甲脒 在 sodium hydroxide 作用下， 生成 N¹,N¹--N³-<3-phenyl-1,2,4-triazolyl-(5)>-guanidin
  参考文献：
  名称：

  Logemann,W. et al., Chemische Berichte, 1963, vol. 96, p. 2914 - 2917

  摘要：

  DOI：
• 作为产物：
  描述：

  cyanocyanamide;morpholine 以30%的产率得到
  参考文献：
  名称：

  Jaeger L., Kretschmann M., Koehler H., L. Anorg. und Allg. Chem., 611 (1992) N 5, S 68-72

  摘要：

  DOI：

文献信息

• ANTIVIRAL AND ANTIMICROBIAL COMPOUNDS
  申请人：Vymed Corporation

  公开号：US20140073631A1

  公开（公告）日：2014-03-13

  Disclosed are guanidine and biguanidine derivatives which have anti-viral and antibacterial activity. Also disclosed are pharmaceutical compositions containing such compounds as an active ingredient, and anti-viral and anti-bacterial methods utilizing such compounds. Methods of treating infections using the guanidine and biguanidine derivatives are also disclosed.

  本文披露了具有抗病毒和抗菌活性的胍和双胍衍生物。还披露了含有这些化合物作为活性成分的药物组合物，以及利用这些化合物的抗病毒和抗菌方法。还披露了使用胍和双胍衍生物治疗感染的方法。
• N1-Cyclic Amine-N5-Substituted Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same
  申请人：Kim Sung Wuk

  公开号：US20140179661A1

  公开（公告）日：2014-06-26

  A N1-cyclic amine-N5-substituted biguanide derivative of Formula 1 or a pharmaceutically acceptable salt thereof, a method of manufacturing the same, and a pharmaceutical composition including the biguanide derivative or the pharmaceutically acceptable salt thereof as an active ingredient are provided. The biguanide derivatives have an effect of inhibiting cancer cell proliferation and also exhibit anticancer activity including inhibition of cancer metastasis and cancer recurrence, because they are effective in activating AMPK, which is associated with the control of energy metabolism, even when administered in a small dose compared with conventional drugs. Also, the biguanide derivatives are highly effective at lowering blood glucose and lipid concentration by AMPK activation, thus they may be effectively used to treat diabetes mellitus, obesity, hyperlipemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndrome and metabolic syndrome.

  提供了一种公式1的N1-环氨基-N5-取代双胍衍生物或其药用盐，以及制造该衍生物的方法，以及包含双胍衍生物或其药用盐作为活性成分的药物组合物。这些双胍衍生物具有抑制癌细胞增殖的效果，并且还表现出抗癌活性，包括抑制癌症转移和癌症复发，因为它们在与传统药物相比仅需小剂量时，能有效激活与能量代谢控制相关的AMPK。此外，双胍衍生物通过激活AMPK在降低血糖和血脂浓度方面具有很高的效果，因此它们可能有效用于治疗糖尿病、肥胖症、高脂血症、高胆固醇血症、脂肪肝、冠状动脉疾病、骨质疏松症、多囊卵巢综合征和代谢综合征。
• N1-Cyclic Amine-N5-Substituted Phenyl Biguanide Derivatives, Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same
  申请人：Kim Sung Wuk

  公开号：US20140179660A1

  公开（公告）日：2014-06-26

  An N1-cyclic amine-N5-substituted phenyl biguanide derivative of Formula 1 or a pharmaceutically acceptable salt thereof, a method of manufacturing the same, and a pharmaceutical composition including the biguanide derivative or the pharmaceutically acceptable salt thereof as an active ingredient are provided. The biguanide derivatives have an effect of inhibiting cancer cell proliferation and also exhibit anticancer activity including inhibition of cancer metastasis and cancer recurrence, because they are effective in activating AMPK, which is associated with the control of energy metabolism, even when administered in a small dose compared with conventional drugs. Also, the biguanide derivatives are highly effective at lowering blood glucose and lipid concentration by AMPK activation, thus they may be effectively used to treat diabetes mellitus, obesity, hyperlipemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndrome and metabolic syndrome.

  提供了一种Formula 1的N1-环氨基-N5-取代苯基双胍衍生物或其药用盐，以及制备该化合物的方法，以及包含该双胍衍生物或其药用盐作为活性成分的药物组合物。这些双胍衍生物具有抑制癌细胞增殖的作用，并且还表现出抗癌活性，包括抑制癌症转移和癌症复发，因为它们能够有效激活与能量代谢控制相关的AMPK，即使与传统药物相比，以小剂量给药也具有显著效果。此外，这些双胍衍生物通过激活AMPK而高效降低血糖和血脂浓度，因此它们可能有效用于治疗糖尿病、肥胖症、高脂血症、高胆固醇血症、脂肪肝、冠心病、骨质疏松症、多囊卵巢综合征和代谢综合征。
• Ueda,T. et al., Chemical and pharmaceutical bulletin, 1971, vol. 19, p. 1990 - 1999
  作者：Ueda,T. et al.

  DOI：——

  日期：——
• SCHRAMM W.; VOSS G.; REMBARZ G.; FISCHER E., Z. CHEM. <ZECE-AL>, 1975, 15, NO 2, 57-58
  作者：SCHRAMM W.、 VOSS G.、 REMBARZ G.、 FISCHER E.

  DOI：——

  日期：——